Momelotinib for myelofibrosis with an enlarged spleen
Part of Blood & lymphatic clinical trials.
This study looks at how well momelotinib works in people with myelofibrosis who have an enlarged spleen. It checks the drug's effects in everyday medical practice, not in a strictly controlled lab setting.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have myelofibrosis, either on its own or after a history of polycythemia vera or essential thrombocythemia
- Your spleen is enlarged and can be felt by the doctor
- Your platelet count is not extremely low (below 20,000)
- You have not taken a JAK inhibitor for a disease other than myelofibrosis
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares two oral drugs, momelotinib and ruxolitinib, for people with myelofibrosis who have low blood cell counts. Both drugs aim to reduce an enlarged spleen and improve symptoms, and this study will see which one works better and with fewer side effects.
This study tests a new combination of two drugs, tagraxofusp and pacritinib, for people with myelofibrosis who have already tried a JAK inhibitor without enough benefit or who couldn't take one. The goal is to see if the combination can shrink the spleen and improve symptoms.
This trial combines two drugs, bomedemstat and momelotinib, to treat myelofibrosis, a rare blood cancer. It aims to see if the combination helps improve blood counts and reduce symptoms when momelotinib alone isn't working well enough.
This trial tests whether the drug momelotinib, given before and after a stem cell transplant (also called a bone marrow transplant), can help people with myelofibrosis. The hope is that it will make the transplant safer and more effective.
This trial tests an experimental drug called PMD-026 for people with myelofibrosis that has not responded well to a JAK inhibitor (like ruxolitinib). The goal is to see if PMD-026 can help reduce symptoms and spleen size.
Hear when a new Myelofibrosis (MF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.